|
業務類別
|
Biotechnology |
|
業務概覽
|
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447. |
| 公司地址
| 1/6 Posthoflei, Antwerp, BEL, 2600 |
| 電話號碼
| +32 33189170 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.agomab.com |
| 員工數量
| 80 |
| Mr. Pierre Kemula, B.Sc. |
Chief Financial Officer |
-- |
23/04/2026 |
| Mr. Paul Van der Horst, PhD |
Chief Business Officer |
-- |
23/04/2026 |
| Mr. Tim Knotnerus |
Chief Executive Officer and Executive Director |
-- |
23/04/2026 |
| Dr. Philippe Wiesel |
Chief Medical Officer |
-- |
23/04/2026 |
| Dr. Andrea Saez |
Chief Development Officer |
-- |
23/04/2026 |
| Ms. Ellen Lefever |
General Counsel |
-- |
23/04/2026 |
|
|
| Mr. David R. Epstein |
Chairman of the Board |
23/04/2026 |
| Mr. Colin Michael Bond |
Independent Director |
23/04/2026 |
| Ms. Felice Weegen Isabel Verduyn-van |
Independent Director |
23/04/2026 |
| Mr. Tim Knotnerus |
Chief Executive Officer and Executive Director |
23/04/2026 |
| Ms. Angelika Jahreis |
Non-Executive Director |
23/04/2026 |
| Mr. Ohad Hammer |
Independent Director |
23/04/2026 |
|
|
|
|
